Unternehmen Acerus Pharmaceuticals Corporation
Aktien
A3DHGW
CA00444G4051
ASPCF
Pharmazeutika
Kurzporträt
Mitarbeiterzahl: 14
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Edward Gudaitis
CEO | Chief Executive Officer | - | 01.05.18 |
Naveed Manzoor
DFI | Director of Finance/CFO | - | - |
Chief Tech/Sci/R&D Officer | - | 17.07.20 | |
Philippe Savard
LAW | General Counsel | - | 04.07.16 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Director/Board Member | 74 | - | |
Ian Ihnatowycz
CHM | Chairman | 71 | 09.09.13 |
Borys Chabursky
BRD | Director/Board Member | - | 20.12.15 |
Edward Gudaitis
CEO | Chief Executive Officer | - | 01.05.18 |
Stephen Gregory
BRD | Director/Board Member | - | 14.07.11 |
Geoff Cotton
BRD | Director/Board Member | - | 01.05.20 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 7 702 297 | 662 312 ( 8,599 %) | 0 | 8,599 % |
Unternehmenskontakt
Acerus Pharmaceuticals Corp.
7025 Langer Drive Suite 205
L5N 0E8, Mississauga
+
http://www.aceruspharma.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+42.83% | 750 Mrd. | |
+34.11% | 606 Mrd. | |
-5.70% | 356 Mrd. | |
+18.06% | 326 Mrd. | |
+4.63% | 286 Mrd. | |
+18.19% | 246 Mrd. | |
-2.94% | 213 Mrd. | |
+11.11% | 213 Mrd. | |
+2.43% | 167 Mrd. |